Group 5A: Metastatic Breast Cancer; ER+; Treatment Resistance; Immunology; Novel Drug

Poster #P4-12-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Advanced or Metastatic Breast Cancer: TACTIVE-U  Prelim Phase 1b Results

Poster #P3-04-18: An immunological mechanism of resistance to CDK4/6 inhibitors in breast cancer